These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20473736)

  • 1. Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia.
    Fan XF; Deng YQ; Ye L; Li YD; Chen J; Lu WW; Li JP
    Chin J Integr Med; 2010 Apr; 16(2):119-23. PubMed ID: 20473736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of ApoE gene polymorphism on anti-inflammatory action of xuezhikang capsule].
    Jiang WM; Fang ZY; Zhu CL; Tang SH
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jan; 33(1):35-9. PubMed ID: 23596783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia.
    Zhu FS; Liu S; Chen XM; Huang ZG; Zhang DW
    World J Gastroenterol; 2008 Nov; 14(41):6395-400. PubMed ID: 19009658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effects of Xuezhikang on serum lipid profile, thromboxane A2 and prostacyclin in patients with hyperlipidemia].
    Jian J; Hao X; Deng C; Zhou H; Lin J
    Zhonghua Nei Ke Za Zhi; 1999 Aug; 38(8):517-9. PubMed ID: 11798687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
    Hong XZ; Li LD; Wu LM
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
    Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK
    Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of traditional chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis.
    Gao Y; Song LX; Jiang MN; Ge GY; Jia YJ
    Inflammation; 2008 Apr; 31(2):121-32. PubMed ID: 18302012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of Qingzhi soft capsule on blood lipid level and pathology of the fatty liver in hyperlipidemic rats].
    Tong L; Chen YY; Guo YL
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jan; 28(1):73-5. PubMed ID: 18227032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triterpenoid-rich fraction from Ilex hainanensis Merr. attenuates non-alcoholic fatty liver disease induced by high fat diet in rats.
    Cui WX; Yang J; Chen XQ; Mao Q; Wei XL; Wen XD; Wang Q
    Am J Chin Med; 2013; 41(3):487-502. PubMed ID: 23711137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of
    Liao J; Liu B; Zhong W; Wang GD; Xu YL; Chen X
    J Biol Regul Homeost Agents; 2019 Jan-Feb,; 33(1):7-17. PubMed ID: 30666855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering effects of Danhong injection on hyperlipidemia rats.
    Chen J; Deng J; Zhang Y; Yang J; He Y; Fu W; Xing P; Wan Ht
    J Ethnopharmacol; 2014 Jun; 154(2):437-42. PubMed ID: 24751362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Protection of huanglian jiedu decoction on systemic and vascular immune responses of high fat induced apoE(-/-) mice].
    Ma YL; Wang BB; Han JY; Li R; Zhang WM; Li T; Chen B; Su J; Wang XB; Zeng H
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Nov; 33(11):1520-5. PubMed ID: 24483114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salusin-α attenuates hepatic steatosis and atherosclerosis in high fat diet-fed low density lipoprotein receptor deficient mice.
    Tang K; Wang F; Zeng Y; Chen X; Xu X
    Eur J Pharmacol; 2018 Jul; 830():76-86. PubMed ID: 29704496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified lingguizhugan decoction incorporated with dietary restriction and exercise ameliorates hyperglycemia, hyperlipidemia and hypertension in a rat model of the metabolic syndrome.
    Yao L; Wei J; Shi S; Guo K; Wang X; Wang Q; Chen D; Li W
    BMC Complement Altern Med; 2017 Feb; 17(1):132. PubMed ID: 28241808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of non-alcoholic fatty liver disease by Qianggan Capsule.
    Li L; Zhang XJ; Lan Y; Xu L; Zhang XZ; Wang HH
    Chin J Integr Med; 2010 Feb; 16(1):23-7. PubMed ID: 20131032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.
    Genc H; Dogru T; Kara M; Tapan S; Ercin CN; Acikel C; Karslioglu Y; Bagci S
    Ann Hepatol; 2013; 12(4):548-55. PubMed ID: 23813132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-κB pathway.
    Chen M; Xing J; Pan D; Peng X; Gao P
    Biomed Pharmacother; 2020 Aug; 128():110286. PubMed ID: 32521450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study of treatment nonalcoholic fatty liver with qianggan capsule].
    Chen ZX; Zhang SJ; Yun LR
    Zhongguo Zhong Yao Za Zhi; 2006 Oct; 31(20):1739-41. PubMed ID: 17225548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of zhitiaokang capsule on serum insulin-like growth factor-2 in patients with hyperlipidemia].
    Yang MX; Su FZ; Yu WT; Tian Y
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Jan; 25(1):30-2. PubMed ID: 15719746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adipokines and cytokines in non-alcoholic fatty liver disease.
    Jarrar MH; Baranova A; Collantes R; Ranard B; Stepanova M; Bennett C; Fang Y; Elariny H; Goodman Z; Chandhoke V; Younossi ZM
    Aliment Pharmacol Ther; 2008 Mar; 27(5):412-21. PubMed ID: 18081738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.